Floatz logo

tng462

RAS Mutation

Tango Therapeutics, Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the RAS Mutation cohort.

Asset / SponsorPhaseRating
Irinotecan
Tango Therapeutics, Inc.
Phase 3B
FLUOROURACILUM
Tango Therapeutics, Inc.
Phase 3B
Cetuximab
Beijing Hospital
Phase 3B
Binimetinib
N.N. Petrov National Medical Research Center of Oncology
Phase 2B
Eloxatin
Tango Therapeutics, Inc.
Phase 2B

View all 25 →

Same molecule, other indications

tng462 is also rated in:

MTAP-deleted Solid TumorsDormant
CC
Indicative ·
47 / 100
View asset →
MTAP DeletionDormant
CC
Indicative ·
45 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →